Prosperity Consulting Group LLC Lowers Stake in GSK PLC Sponsored ADR (NYSE:GSK)

Prosperity Consulting Group LLC lowered its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 4.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,482 shares of the pharmaceutical company’s stock after selling 1,188 shares during the period. Prosperity Consulting Group LLC’s holdings in GSK were worth $910,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of GSK. Richardson Financial Services Inc. lifted its holdings in shares of GSK by 127.9% during the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company’s stock valued at $33,000 after purchasing an additional 472 shares during the last quarter. Olde Wealth Management LLC purchased a new stake in shares of GSK during the 1st quarter valued at $36,000. First Pacific Financial purchased a new stake in shares of GSK during the 1st quarter valued at $45,000. CX Institutional acquired a new position in shares of GSK in the 1st quarter valued at $46,000. Finally, Garde Capital Inc. acquired a new position in shares of GSK in the 1st quarter valued at $51,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Wall Street Zen downgraded GSK from a “buy” rating to a “hold” rating in a research report on Saturday. Berenberg Bank reissued a “hold” rating on shares of GSK in a research report on Tuesday, June 3rd. Hsbc Global Res raised GSK to a “strong sell” rating in a research report on Monday, April 28th. Finally, BNP Paribas assumed coverage on GSK in a research report on Tuesday, April 15th. They issued a “neutral” rating and a $35.25 target price on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a strong buy rating to the company. According to data from MarketBeat, GSK has a consensus rating of “Hold” and a consensus target price of $37.38.

GSK Price Performance

Shares of GSK opened at $37.49 on Tuesday. The business’s 50-day moving average is $39.02 and its two-hundred day moving average is $37.59. The company has a market capitalization of $76.54 billion, a P/E ratio of 19.32, a P/E/G ratio of 1.55 and a beta of 0.50. The company has a debt-to-equity ratio of 1.21, a quick ratio of 0.58 and a current ratio of 0.87. GSK PLC Sponsored ADR has a fifty-two week low of $31.72 and a fifty-two week high of $44.67.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.05. The company had revenue of $10.06 billion for the quarter, compared to the consensus estimate of $7.52 billion. GSK had a return on equity of 48.82% and a net margin of 9.89%. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period last year, the firm earned $0.43 EPS. Research analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, July 10th. Shareholders of record on Friday, May 16th were given a dividend of $0.4216 per share. This is an increase from GSK’s previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a yield of 4.50%. The ex-dividend date was Friday, May 16th. GSK’s dividend payout ratio (DPR) is currently 88.14%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.